2026年7月24日，复星医药（02196）公告，其控股子公司复星万邦（江苏）医药集团有限公司已收到国家药品监督管理局关于同意DM1001制剂用于治疗成人特发性帕金森病体征和症状的临床试验批准。复星万邦计划在条件具备后于中国境内启动I期临床试验。 公告显示，DM1001为化学药物。截至2026年6月，复星医药及控股子公司针对DM1001的累计研发投入约为人民币695万元（未经审计）。根据IQVIA CHPA数据，2025年相同化合物药品在中国的销售额约为人民币3.75亿元。 公司提示，DM1001仍需在中国开展后续临床研究并通过药品审评部门审批后方可上市，药物研发存在安全性、有效性等不确定性风险，投资者需关注相关风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.